CR20210616A - Formas de sales cristalinas de un inhibidor de cinasas - Google Patents

Formas de sales cristalinas de un inhibidor de cinasas

Info

Publication number
CR20210616A
CR20210616A CR20210616A CR20210616A CR20210616A CR 20210616 A CR20210616 A CR 20210616A CR 20210616 A CR20210616 A CR 20210616A CR 20210616 A CR20210616 A CR 20210616A CR 20210616 A CR20210616 A CR 20210616A
Authority
CR
Costa Rica
Prior art keywords
kinase inhibitor
salt forms
crystalline salt
relates
compound
Prior art date
Application number
CR20210616A
Other languages
English (en)
Inventor
Courtney S Johnson
Peter Wong
Frenel Demorin
Sagar Shakya
Melanie Janelle Bevill
Stephan D Parent
Khalid Shah
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of CR20210616A publication Critical patent/CR20210616A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La presente invención está relacionada con las formas cristalinas de sales del Compuesto 1. La invención también está relacionada con composiciones farmacéuticas que comprenden las sales cristalinas sólidas del Compuesto 1. La invención está relacionada además con métodos de tratamiento de una enfermedad, un trastorno o un síndrome mediado al menos en parte por la modulación de la actividad <em>in vivo</em> de una proteína cinasa.
CR20210616A 2019-06-03 2019-12-12 Formas de sales cristalinas de un inhibidor de cinasas CR20210616A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962856404P 2019-06-03 2019-06-03
PCT/US2019/065980 WO2020247019A1 (en) 2019-06-03 2019-12-12 Crystalline salt forms of a kinase inhibitor

Publications (1)

Publication Number Publication Date
CR20210616A true CR20210616A (es) 2022-03-22

Family

ID=69160360

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210616A CR20210616A (es) 2019-06-03 2019-12-12 Formas de sales cristalinas de un inhibidor de cinasas

Country Status (18)

Country Link
US (1) US20230052703A1 (es)
EP (1) EP3976587A1 (es)
JP (1) JP2022535072A (es)
KR (1) KR20220016117A (es)
CN (1) CN113939503B (es)
AU (1) AU2019449809A1 (es)
BR (1) BR112021024300A2 (es)
CA (1) CA3139148A1 (es)
CL (1) CL2021003205A1 (es)
CO (1) CO2021017343A2 (es)
CR (1) CR20210616A (es)
DO (1) DOP2021000236A (es)
IL (1) IL288484A (es)
MA (1) MA56001A (es)
MX (1) MX2021014773A (es)
PE (1) PE20220962A1 (es)
SG (1) SG11202111978VA (es)
WO (1) WO2020247019A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020015201A2 (pt) * 2018-01-26 2020-12-29 Exelixis, Inc. Compostos para tratamento contra distúrbios dependentes de quinase
US20230029213A1 (en) * 2018-12-13 2023-01-26 Exelixis, Inc. Crystalline Forms and Salt Forms of a Kinase Inhibitor
TW202334090A (zh) * 2021-11-03 2023-09-01 美商艾克塞里克斯公司 用於治療激酶依賴性病症之化合物
TW202340148A (zh) 2021-12-22 2023-10-16 美商艾克塞里克斯公司 激酶抑制劑之結晶形式及鹽形式

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2466818T3 (es) * 2003-09-26 2014-06-11 Exelixis, Inc. Moduladores c-Met y métodos de uso
EP1871417B1 (en) 2005-04-15 2013-09-11 Precision Biologics, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
CA3139031A1 (en) 2012-10-04 2014-04-10 Dana-Farber Cancer Institute, Inc. Human monoclonal anti-pd-l1 antibodies and methods of use
US9815897B2 (en) 2013-05-02 2017-11-14 Anaptysbio, Inc. Antibodies directed against programmed death-1 (PD-1)
US20180009758A1 (en) * 2015-06-29 2018-01-11 Ontogenesis, Llc Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use
MX2019012505A (es) * 2017-05-26 2019-12-19 Exelixis Inc Formas solidas cristalinas de sales de ciclopropano-1,1-dicarboxam ida de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofen il), procesos para realizarlas y metodos de uso.
BR112020015201A2 (pt) 2018-01-26 2020-12-29 Exelixis, Inc. Compostos para tratamento contra distúrbios dependentes de quinase
CN109761899B (zh) * 2019-02-14 2022-11-15 广州六顺生物科技股份有限公司 喹啉衍生物、其药学上可接受的盐或其溶剂合物、其应用、药物及药物组合物

Also Published As

Publication number Publication date
US20230052703A1 (en) 2023-02-16
AU2019449809A1 (en) 2021-12-16
CN113939503B (zh) 2024-05-07
IL288484A (en) 2022-01-01
CN113939503A (zh) 2022-01-14
BR112021024300A2 (pt) 2022-01-11
DOP2021000236A (es) 2022-04-18
CO2021017343A2 (es) 2022-01-17
EP3976587A1 (en) 2022-04-06
MX2021014773A (es) 2022-01-18
KR20220016117A (ko) 2022-02-08
PE20220962A1 (es) 2022-06-10
CA3139148A1 (en) 2020-12-10
JP2022535072A (ja) 2022-08-04
CL2021003205A1 (es) 2022-09-30
MA56001A (fr) 2022-04-06
WO2020247019A1 (en) 2020-12-10
SG11202111978VA (en) 2021-11-29

Similar Documents

Publication Publication Date Title
CR20210375A (es) Formas cristalinas y formas de sal de un inhibidor de cinasa
CR20210616A (es) Formas de sales cristalinas de un inhibidor de cinasas
EA201792214A1 (ru) Соединения замещенного хиназолина
EA201690752A1 (ru) Ингибиторы g12c kras
EA201991884A2 (ru) Ингибиторы g12c kras
PH12020552187A1 (en) Pcsk9 antagonist compounds
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
CR20200263A (es) Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5
MX2021015935A (es) Formas de sal de acido bempedoico y metodos para utilizar el mismo.
CR20230310A (es) Inhibidores de prmt5
EA200702339A1 (ru) Замещенные амидные производные в качестве ингибиторов протеинкиназы
MX2021011606A (es) Compuestos dirigidos a prmt5.
MX2020012978A (es) Sales de sepiapterina farmacéuticamente aceptables.
MX2012003007A (es) Sulfonamidas como inhibidores de las proteinas de la familia bcl-2 para el tratamiento de cancer.
MX2023010303A (es) Metodo de modulacion de las vias de se?alizacion de tigit y pd-1 mediante el uso de compuestos de 1,2,4-oxadiazol.
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
MX2021010700A (es) Compuestos utiles en la terapia del vih.
MX2021012105A (es) Compuestos de pirrol.
MX2022002597A (es) Métodos de tratamiento de la epilepsia usando los métodos.
MX2021012248A (es) Polimorfos de voruciclib y metodos de elaboracion y uso de los mismos.
CR20230223A (es) Composiciones farmacéuticas de un inhibidor de cinasa
PH12019501566A1 (en) Amide compounds and use thereof
MX2022006735A (es) Análogos de nucleósidos sustituidos como inhibidores de la prmt5.
CR20220010A (es) Inhibidores de prmt5
MX2021014228A (es) Formas cristalinas de sal de n-(4-(4 (ciclopropilmetil)piperazin 1- carbonil)fenil)quinolin-8-sulfonamida.